Literature DB >> 22381321

The paradigm of skull base meningiomas: what is optimal?

Basant Kumar Misra1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22381321     DOI： 10.1016/j.wneu.2011.11.018

Source DB:  PubMed          Journal:  World Neurosurg        ISSN： 1878-8750            Impact factor:   2.104


× No keyword cloud information.
  5 in total

1.  Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.

Authors:  Shuyu Hao; Guanyou Huang; Jie Feng; Da Li; Ke Wang; Liang Wang; Zhen Wu; Hong Wan; Liwei Zhang; Junting Zhang
Journal:  J Neurooncol       Date:  2019-06-08       Impact factor: 4.130

2.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

3.  Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography.

Authors:  Mats Ryttlefors; Torsten Danfors; Francesco Latini; Anders Montelius; Erik Blomquist; Olafur Gudjonsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-28       Impact factor: 9.236

4.  Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas.

Authors:  Pavlos Vlachogiannis; Olafur Gudjonsson; Anders Montelius; Erik Grusell; Ulf Isacsson; Kristina Nilsson; Erik Blomquist
Journal:  Acta Neurochir (Wien)       Date:  2017-10-24       Impact factor: 2.216

5.  Primary versus postoperative gamma knife radiosurgery for intracranial benign meningiomas: a matched cohort retrospective study.

Authors:  Junyi Fu; Jiamin Zeng; Minyi Huang; Shunyao Liang; Yong He; Longchang Xie; Yinhui Deng; Jinxiu Yu
Journal:  BMC Cancer       Date:  2022-02-24       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.